Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK: Cytyc's Novasure awaits NICE (National Institute for Clinical Excellence) verdict

This article was originally published in Clinica

Executive Summary

Cytyc has launched its Novasure radiofrequency endometrial ablation system in the UK, as part of plans to expand its EU market coverage of the technology. The impedance-controlled bipolar ablation system used to treat menorrhagia (heavy menstrual bleeding) was CE-marked in 2002, but Novasure's real success in the UK is set to hinge on the current assessment of the technology by the National Institute for Clinical Excellence (NICE).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel